Literature DB >> 34844708

Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Tilo Freiwald1, Behdad Afzali2.   

Abstract

The complement system is an ancient and phylogenetically conserved key danger sensing system that is critical for host defense against pathogens. Activation of the complement system is a vital component of innate immunity required for the detection and removal of pathogens. It is also a central orchestrator of adaptive immune responses and a constituent of normal tissue homeostasis. Once complement activation occurs, this system deposits indiscriminately on any cell surface in the vicinity and has the potential to cause unwanted and excessive tissue injury. Deposition of complement components is recognized as a hallmark of a variety of kidney diseases, where it is indeed associated with damage to the self. The provenance and the pathophysiological role(s) played by complement in each kidney disease is not fully understood. However, in recent years there has been a renaissance in the study of complement, with greater appreciation of its intracellular roles as a cell-intrinsic system and its interplay with immune effector pathways. This has been paired with a profusion of novel therapeutic agents antagonizing complement components, including approved inhibitors against complement components (C)1, C3, C5 and C5aR1. A number of clinical trials have investigated the use of these more targeted approaches for the management of kidney diseases. In this review we present and summarize the evidence for the roles of complement in kidney diseases and discuss the available clinical evidence for complement inhibition. 2021 Published by Elsevier Inc.

Entities:  

Keywords:  Avacopan; C3; C5; Complement inhibitors; Complement system; Complosome; Eculizumab; Immunology; Kidney disease

Mesh:

Substances:

Year:  2021        PMID: 34844708      PMCID: PMC8905641          DOI: 10.1016/bs.ai.2021.09.001

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  502 in total

1.  The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy.

Authors:  Roland Schmitt; Anne-Lie Ståhl; Anders I Olin; Ann-Charlotte Kristoffersson; Johan Rebetz; Jan Novak; Gunnar Lindahl; Diana Karpman
Journal:  J Immunol       Date:  2014-05-21       Impact factor: 5.422

Review 2.  Complement in ANCA-associated vasculitis: mechanisms and implications for management.

Authors:  Min Chen; David R W Jayne; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-03-20       Impact factor: 28.314

3.  A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats.

Authors:  Thiruma V Arumugam; Ian A Shiels; Anna J Strachan; Giovani Abbenante; David P Fairlie; Stephen M Taylor
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  Eculizumab treatment for rescue of renal function in IgA nephropathy.

Authors:  Therese Rosenblad; Johan Rebetz; Martin Johansson; Zivile Békássy; Lisa Sartz; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2014-06-13       Impact factor: 3.714

5.  Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation.

Authors:  Bart De Vries; Robert A Matthijsen; Tim G A M Wolfs; Annemarie A J H M Van Bijnen; Peter Heeringa; Wim A Buurman
Journal:  Transplantation       Date:  2003-02-15       Impact factor: 4.939

6.  Role of terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis.

Authors:  G C Groggel; D J Salant; C Darby; H G Rennke; W G Couser
Journal:  Kidney Int       Date:  1985-04       Impact factor: 10.612

7.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Authors:  Marina Noris; Miriam Galbusera; Sara Gastoldi; Paolo Macor; Federica Banterla; Elena Bresin; Claudio Tripodo; Serena Bettoni; Roberta Donadelli; Elisabetta Valoti; Francesco Tedesco; Alessandro Amore; Rosanna Coppo; Piero Ruggenenti; Eliana Gotti; Giuseppe Remuzzi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

8.  Is primary membranous nephropathy a complement mediated disease?

Authors:  Linda Reinhard; Rolf A K Stahl; Elion Hoxha
Journal:  Mol Immunol       Date:  2020-11-01       Impact factor: 4.407

9.  Circulating immune complexes and complement breakdown product C3d in glomerulonephritis and kidney transplantation.

Authors:  J Sølling
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1984-08

10.  A pro-inflammatory role of C5L2 in C5a-primed neutrophils for ANCA-induced activation.

Authors:  Jian Hao; Chen Wang; Jun Yuan; Min Chen; Ming-Hui Zhao
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more
  1 in total

1.  Locally generated C3 regulates the clearance of Toxoplasma gondii by IFN-γ-primed macrophage through regulation of xenophagy.

Authors:  Bo Liu; Yan Yan; Xiaoreng Wang; Nannan Chen; Jue Wu
Journal:  Front Microbiol       Date:  2022-08-04       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.